Stay updated on Zimmer Biomet with Becker's as they report on recent updates, including sales growth, a new acquisition, and a successful surgery.

Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company specializing in musculoskeletal healthcare ...

Zimmer Biomet recently announced entering a definitive agreement to acquire all outstanding common shares of Paragon 28. Under the agreement, ...

Zimmer Biomet to acquire Paragon 28 for $13/share, totaling $1.2B in enterprise value. Deal expected to close in H1 2025, with potential $1/share CVR based on 2026 sales milestones. Get real-time ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025 Management View CEO Dave Rosa highlighted the strong performance of the OneRF ablation system, which is the first FDA-cleared product ...

Stock analysts at Roth Capital issued their Q1 2025 earnings estimates for Zimmer Biomet in a research note issued on Friday, February 7th. Roth Capital analyst J. Wittes forecasts that the medical ...

Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $118 and keeps an Underweight rating on the shares. The firm ...

Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...

Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Zimmer Biomet beat analysts’ revenue expectations by ...

When shares of Zimmer Biomet (NYSE:ZBH) moved down to the $105 mark in September, I believed that real value was showing up. Shares sold off despite the projection of mid-single digit sales growth ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...